VALENCIA, Calif., Oct. 26 /PRNewswire-FirstCall/ -- MannKind Corporation focused on discovering, developing and commercializing treatments for diabetes and cancer, announced the following today:
* The Company will release its 2006 third quarter financial results on Thursday, November 2, 2006 at 7:00 a.m. ET * The Company will present at the Rodman & Renshaw 8th Annual Healthcare Conference on Monday, November 6, 2006 at 3:20 PM ET at New York Palace Hotel in New York City * The Company will present at the CIBC World Markets 17th Annual Healthcare Conference on Tuesday, November 7, 2006 at 10:55 AM ET at The Waldorf-Astoria in New York City Third Quarter Financial Results
Management of the Company will host a conference call to discuss the third quarter financial results, clinical progress and other Company developments at 9:00 a.m. ET on Thursday, November 2, 2006. Presenting from the Company will be its Chairman and Chief Executive Officer, Alfred Mann; President and Chief Operating Officer, Hakan Edstrom; and Corporate Vice President and Chief Financial Officer, Dick Anderson.
To participate in the live call by telephone, please dial (888) 566-5775 or (210) 839-8503. Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at www.mannkindcorp.com.
A telephone replay of the call will be available for 48 hours by dialing (866) 394-7039 or (203) 369-0463 and entering passcode "MNKD". A replay will be available on MannKind's website for fourteen days.
Conference Presentations
Interested parties can access a link to the live web cast of each presentation in the Investor Relations section of the Company's website at www.mannkindcorp.com. A replay of each presentation will be available for 14 days.
About MannKind Corporation
MannKind Corporation focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Its lead product, the Technosphere(R) Insulin System, is currently in phase 3 clinical trials in the U.S., Europe and Latin America to study its safety and efficacy in the treatment of diabetes. For more information on MannKind Corporation and its technology, visit www.mannkindcorp.com.
MannKind CorporationCONTACT: Dick Anderson, Chief Financial Officer of MannKind Corporation,+1-661-775-5302, danderson@mannkindcorp.com; or Investor Relations, JulieHuang of Financial Dynamics, +1-212-850-5628, mnkd@fd.com, for MannKindCorporation
Web site: http://www.mannkindcorp.com/
